TBTatiana Pavlovna Berezovskaya

Tatiana Pavlovna Berezovskaya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tatiana Pavlovna Berezovskaya has a total of 110 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sigmoid cancer in a diverticulum (a case report and review)

    by T. P. Berezovskay, A. Nevolskikh, Ya. A. Daineko, V. A. Avdeenko, I. P. Reznik, V. N. Grinevich

    AIM: to present and discuss the challenges of radiological and endoscopic diagnosis of cancer within a colonic diverticulum in patients with diverticulitis, using a clinical case as an example. PATIENTS AND METHODS: a 76-year-old female patient underwent clinical and instrumental examination for exacerbation of sigmoid diverticular disease. RESULTS: based on the findings of radiological and endoscopic examinations, a chronic pericolonic inflammatory infiltrate of the sigmoid colon involving the uterine stump was identified, showing signs of neoplastic growth within a diverticulum, as well as a tumor in the ascending colon. The patient underwent simultaneous right hemicolectomy and combined anterior resection of the rectum with extirpation of the uterine stump. Pathomorphological examination revealed a poorly differentiated adenocarcinoma with signs of impaired DNA mismatch repair (dMMR) within the diverticulum, and a tumor in the ascending colon with similar characteristics. CONCLUSION: cancer arising in a colonic diverticulum presents a complex diagnostic challenge due to its unique growth patterns and the need to differentiate it from complicated forms of diverticular disease. In such cases, a thorough and comprehensive clinical and instrumental examination is necessary for adequate planning of surgical treatment.

  • Open Access

    First experience with whole-body magnetic resonance imaging using MET-RADS-P criteria for interim efficacy evaluation of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer

    by Tatiana P. Berezovskaia, Vladislav O. Ripp, Tatiana Yu. Kochetova, Valeriy V. Krylov, Sergei A. Ivanov, Andrei D. Kaprin, Березовская Татьяна Павловна

    BACKGROUND: Radioligand therapy with actinium-225–prostate-specific membrane antigen (225Ac-PSMA) is a novel and promising treatment modality for metastatic castration-resistant prostate cancer. Whole-body magnetic resonance imaging (WB-MRI) is a noninvasive, non-ionizing imaging technique that provides comprehensive information on skeletal and extraskeletal metastatic lesions, structured using the MET-RADS-P (METastasis Reporting and Data System for Prostate Cancer) and enabling detailed assessment of treatment response. However, the use of this system has not been widely adopted, and its diagnostic accuracy requires clinical validation. AIM: This study aimed to evaluate the interim efficacy of 225Ac-PSMA radioligand therapy using WB-MRI based on MET-RADS-P criteria in patients with metastatic castration-resistant prostate cancer, assess method reproducibility (intra-observer agreement), and compare imaging findings with changes in prostate-specific antigen (PSA) levels. METHODS: WB-MRI was performed twice in patients with metastatic castration-resistant prostate cancer: before administration of 225Ac-PSMA-617 with activity 6–12 MBq and 1–2 months after a single cycle of radioligand therapy, with parallel measurement of PSA levels. Prospective response assessment was conducted using MET-RADS-P criteria for WB-MRI and PCWG criteria for PSA level trends. Reproducibility of MET-RADS-P criteria was evaluated through repeated reading of WB-MRI studies by the same radiologist with a 6-month interval. RESULTS: After one cycle of radioligand therapy, MET-RADS-P progression was identified in 4 of 20 patients with metastatic castration-resistant prostate cancer (20%) who completed the study. In three of these patients, progression was detected at an earlier time point than indicated by PSA level trends. More than half of the patients demonstrated discordant responses, including three with progression. Differences in PSA level trends were observed between concordant positive responses and various patterns of discordant response according to MET-RADS-P criteria. In cases of concordant response, the MET-RADS-P integrated assessment showed good correlation with biochemical response. MET-RADS-P criteria demonstrated excellent reproducibility for the primary response category pattern and for integrated response assessment. Reproducibility for the secondary response category pattern was substantial. CONCLUSION: The use of MET-RADS-P criteria to WB-MRI in patients with metastatic castration-resistant prostate cancer enabled earlier detection of progression in skeletal and extraskeletal lesions compared with PSA level trends and demonstrated good intra-observer agreement. Further investigation of the prognostic value of MET-RADS-P criteria in the context of 225Ac-PSMA radioligand therapy is warranted.

  • Open Access

    Active surveillance program of patients with rectal cancer with a complete clinical response after prolonged chemoradiotherapy with consolidating chemotherapy

    by A. A. Nevolskikh, V. A. Avdeenko, T. P. Berezovskaya, T. P. Pochuev, Ya. A. Daineko, Yu. Yu. Mikhaleva, S. A. Myalina, P. V. Sinyaev, S. A. Ivanov, A. D. Kaprin, et al.

    AIM: to determine the algorithm for selecting patients included in the ASP program after prolonged chemoradiotherapy (CRT) with consolidation chemotherapy (CCT).PATIENTS AND METHODS: the retrospective study included patients with adenocarcinoma of the low and middle rectum (2017 to 2024), who achieved cCR after CRT with CCT, which led to the decision to implement ASP. Radiotherapy was administered in a prolonged mode at a dose of 50–55 Gy with oral capecitabine intake. Between the completion of CRT and the first follow-up examination, 4 cycles of CCT were done in the FOLFOX6 regimen. Clinical tumor regression was assessed 4 weeks after the completion of CCT, based on the data from endoscopy, digital examination, and MRI. cCR was understood to refer to cases where, during endoscopic treatment performed after CRT and CCT at the site of the previously determined tumor, there were signs of a flat white/red scar.RESULTS: the study included 27 patients (15 (55.6%) men, 12 (44.4%) women). The patients' age ranged from 38 to 80 years (median 63 years). The median distance from the anal verge to the lower edge of the tumor was 4.5 (2.0–9.5) cm. Most patients had clinical stage III disease — 18/27 (66.7%), while the tumor size in the largest dimension ranged from 2.4 to 6.5 cm (median 4.0 cm). The median interval between the completion of CRT and the follow-up examination was 16 (9–25) weeks. MRI of the pelvic organs revealed TRG1 in 13/27 (48.1%) patients, TRG2 also in 13/27 (48.1%) and in one patient (3.7%) has a mucinous tumor that is not subject to standard TRG assessment. The MRI findings of all patients selected for ASP was characterized by fibrosis of the tumor bed without signs of residual tumor tissue/affected lymph nodes in the mesorectal tissue and deep layers of the wall, while both thin and full-thickness and split fibrous scars present, extending up to half the circumference. All patients who achieved cCR had a primary tumor of category up to T3b inclusive. With a median follow-up of 14.7 (3.8–80.2) months, tumor regrowth was observed in 2/27 patients (7.4%), both of whom underwent radical surgeries. Three-year relapse-free survival rate was 81.1 ± 10.1%, while overall survival 95.2 ± 4.6%.CONCLUSIONS: the implementation of an ASP program after CRT should be based on careful selection of patients who have achieved cCR according to comprehensive check-up. It is advisable to begin the examination with MRI followed by endoscopy, as this approach provides all necessary information and avoids artifacts in MRI that may arise after endoscopy. Endoscopy plays a leading role in assessing the intraluminal tumor component, with the only manifestation of cCR being a flat white or red scar.

  • Open Access

    Chemoradiotherapy in the Combined Treatment of Patients with Rectal Cancer: Experience of A. Tsyb MRRC

    by Алексей Алексеевич Невольских, Виолетта Андреевна Авдеенко, Руслан Фяритович Зибиров, Юлия Юрьевна Михалёва, Дарья Валерьевна Белова, Тарас Петрович Почуев, Иван Анатольевич Орехов, Леонид Олегович Петров, Людмила Николаевна Титова, Игорь Александрович Гулидов, et al.

    Введение. Стандартом лечения больных нижне- и среднеампулярным раком прямой кишки (РПК) является сочетание лучевой и химиотерапии с тотальной мезоректумэктомией (ТМЭ), при этом только у 15 % пациентов при использовании стандартной химиолучевой терапии (ХЛТ) в дозе 50 Гр в сочетании с препаратами фторпиримидинового ряда наблюдается полный патоморфологический ответ на лечение (pCR). Применение консолидирующей химиотерапии (КХТ) в интервале между ХЛТ и операцией направлено на увеличение выживаемости больных и позволяет увеличить количество полных ответов опухоли на лечение. Цель. Анализ непосредственных и отдаленных результатов применения химиолучевой терапии с 4 циклами КХТ в лечении больных местно-распространенным РПК. Материал и методы. В МРНЦ им. А.Ф. Цыба при лечении местно-распространенного РПК с 2018 г. применяется ХЛТ с 4 циклами КХТ. В данном исследовании всем пациентам было запланировано проведение лучевой терапии в суммарной очаговой дозе (СОД) 50 Гр в сочетании с пероральным приемом капецитабина в суточной дозе 825 мг/м2. Конвенциональное облучение проводили на линейном ускорителе методикой четырехпольного изоцентрического облучения. Пациентам, включенным в исследование с июня 2021 г., проводили конформную лучевую терапию с использованием технологий ротационной лучевой терапии с объемной модуляцией интенсивности излучения (VMAT — RapidArc), объемной визуализации мишени IGRT (CBCT). Результаты. В исследование было включено 192 пациента с РПК нижне- и среднеампулярного отделов. У большинства пациентов имелась III клиническая стадия заболевания — 79,2 % (n = 152). Лучевая терапия в полном объеме была завершена у 190 (98,9 %) пациентов. При контрольном обследовании cCR ответ был зарегистрирован у 20 (10,4 %) пациентов. Тринадцать (65,0 %) из них были включены в группу активного динамического наблюдения (АДН). В 7 случаях пациентам с cCR были выполнены хирургические вмешательства. Хирургическое лечение в объеме ТМЭ было выполнено 147 (76,6 %) пациентам, при этом pCR из них был отмечен в 31 (21,1 %) случае. Общая частота полных ответов с учетом пациентов, включенных в АДН (cCR+pCR), составила 27,1 % (52 случая). Общая трехлетняя выживаемость всей группы пациентов составила 82,5 ± 3,2 %. Выводы. ХЛТ с 4 циклами КХТ является безопасным методом лечения, применение которого приводит к полному ответу у 27,1 % пациентов. Применение методики АДН показано пациентам с полным клиническим ответом (cCR). Необходимо дальнейшее совершенствование методов инструментальной диагностики у пациентов с хорошим ответом на ХЛТ (mrTRG1-2) с целью выявления cCR.


  • Open Access

    Prediction of the efficacy of neoadjuvant chemoradiotherapy in patients with rectal cancer based on a texture analysis of T2-weighted magnetic resonance tumor image obtained at primary staging

    by Yana A. Dayneko, Tatiana P. Berezovskaya, Oleg A. Mirzeabasov, Sergey Olegovich Starkov, Sofiya A. Myalina, Aleksey A. Nevolskikh, Sergey А. Ivanov, Andrey D. Kaprin, Дайнеко Яна Александровна, Березовская Татьяна Павловна, et al.

    BACKGROUND: Recently, significant efforts have been undertaken to find potential noninvasive biomarkers for predicting the response of locally advanced rectal cancer to neoadjuvant chemoradiotherapy. AIM: To assess the texture characteristics of locally advanced rectal cancer in primary T2-weighted imaging (T2-WI) as a potential predictor for the efficacy of standard neoadjuvant chemoradiotherapy and develop a prediction system for the efficacy of neoadjuvant chemoradiotherapy based on them. MATERIALS AND METHODS: The retrospective study enrolled 82 patients with locally advanced rectal cancer who received combination treatment with neoadjuvant chemoradiotherapy. Patient data were divided into the training (n=58) and control (n=24) sets. For texture analysis, primary high-resolution T2-WI at the level of the tumor center, oriented perpendicular to the intestinal wall, was used. The texture analysis was performed by second-order statistics based on the gray-level co-occurrence matrices using MAZDA ver. 4.6 featuring the calculation of 11 texture parameters. In the training set, based on the morphological assessment of surgical specimens, significantly different texture analysis parameters were found for two groups of patients: neoadjuvant chemoradiotherapy responders (good prognosis group) and nonresponders (poor prognosis group). Accordingly, a scoring system was created for assessing the efficacy of neoadjuvant chemoradiotherapy. The system was tested on the control set, and diagnostic efficacy parameters were determined. RESULTS: In the training set, the good and poor prognosis groups differed significantly in five texture parameters: AngScMom (p=0.021), SumofSqs (p=0.003), SumEntrp (p=0.003), Entropy (p=0.038), and SumVarnc (p=0.015), for which the cutoff points were found. These parameters were applied to create the scoring system (excluding the Entropy parameter, which had a strong direct correlation with SumEntrp and the lowest area under the curve, and SumofSqs, which had low reproducibility). The diagnostic efficiency of the scoring system for predicting the response had sensitivity, specificity, positive-predictive value, and negative- predictive value of 72%, 69%, 70%, and 71% for the training set and 80%, 64%, 62%, and 82% for the control set, respectively. The areas under the ROC curve were 0.77 and 0.72 for the training and control sets, respectively. CONCLUSIONS: Texture analysis of the primary T2-WI of tumors in patients with locally advanced rectal cancer allows for predicting the efficacy of neoadjuvant chemoradiotherapy with moderate diagnostic efficiency. The results suggest good prospects for further research in this area.

  • Open Access

    Whole body magnetic resonance imaging (WB MRI) in the diagnosis and evaluation of the effectiveness of treatment of metastatic prostate cancer: Met-RADS-P system standards

    by T. P. Berezovskaya, V. O. Ripp, A. V. Troyanov, S. A. Ivanov, A. D. Kaprin

    INTRODUCTION: Whole-body magnetic resonance imaging (WB MRI) including diffusion-weighted imaging (DWI) is increasingly used in clinical practice. For metastatic prostate cancer, the radiologic reporting and data system Met-RADS-P (METastasis Reporting and Data System for Prostate Cancer) has been proposed to determine the prevalence of the metastatic process and subsequently evaluate the response to specific treatment based on WB MRI data.OBJECTIVE: To present an overview of the methodological aspects of WB MRI in patients with metastatic prostate cancer in relation to the Met-RADS-P system, to outline its terminology and principles for assessing study results, and to discuss the possibilities of its clinical use.MATERIALS AND METHODS: A search was conducted for publications for the period from January 1, 2017 to December 1, 2023 in Russian and English in the electronic databases eLibrary, Medline, PubMed, using the keywords: «диффузионно-взвешенная томография всего тела», «метастатический рак предстательной железы», «Met-RADS-P», «Whole Body MRI, WB MRI», «Whole Body DWI, WB DWI», «metastatic prostate cancer», supplemented by examination of references in the retrieved articles.RESULTS: Based on the literature data and our own experience, WB MRI protocols in patients with metastatic prostate cancer are described, the algorithm of MR image analysis, the criteria for evaluating the response of metastatic foci in the skeleton, lymph nodes, and internal organs, and the response assessment categories according to the RAC (response assessment categories) scale, as well as summarize the results and discuss the prospects for the clinical use of Met-RADS-P.DISCUSSION: The few publications in the literature using the Met-RADS-P system primarily concern the assessment of its reliability (inter-reader agreement). The authors conclude that it is appropriate to use it in monitoring metastases in patients with castration-resistant prostate cancer, emphasizing the clinical importance of identifying discordant responses after therapy. They also note the obstacles to the widespread introduction of WB MRI imaging into clinical practice, including the duration of the examination procedure and the large volume of diagnostic data that requires significant time for analysis and reporting, which can be overcome by automating the assessment of MR images using artificial intelligence.CONCLUSION: The Met-RADS-P system systematizes the approach to performing and describing WB MRI in patients with advanced prostate cancer, allowing the technique to be reproduced on virtually any modern scanner, from the scan protocol to a standardized report of findings. This makes the WB MRI technique reproducible in a variety of medical settings, and therefore increases its value. Nevertheless, Met-RADS-P is a relatively new system and requires large multicenter clinical trials to confirm its efficacy and representativeness, as well as to level out its shortcomings.


  • Open Access

    Transanal endoscopic microsurgery after radiation or chemoradiation therapy for rectal cancer — peculiarities and results

    by А. А. Невольских, A. R. Brodskiy, V. A. Avdeenko, T. P. Pochuev, Yu. Yu. Mihaleva, T. P. Berezovskaya, R. F. Zibirov, S. A. Myalina, I. A. Orehov, L. O. Petrov, et al.

    Трансанальные эндомикрохирургические вмешательства при раке прямой кишки после лучевой или химиолучевой терапии — нюансы и результаты


  • Open Access

    Imaging of cervical cancer. Consensus of experts

    by N. A. Rubtsova, T. P. Berezovskaia, V. G. Bychenko, E. A. Pavlovskaya, A. E. Solopova, T. A. Agababyan, M. M. Khodzhibekova, D. V. Ryzhkova, M. A. Chekalova, I. E. Meshkova, et al.

    The article offers the latest view on possibilities of diagnostic algorithm to identify cervical cancer (CC), one of the most incidental tumor of the woman’s reproductive system. The algorithm is described as a consensus of leading expert in imaging diagnostics, as well as oncogynecologysts, investigating diagnostic challenges and cervical cancer therapies. The article sets forth the principal trends in using imaging methods, their role and possibilities for staging CC, planning and assessing the efficacy of applied therapy, on-going surveillance over patients, who have undergone specialized anti-cancer treatment.


  • Open Access

    Imaging of vaginal cancer. Consensus of experts

    by V. A. Solodkiy, N. V. Nudnov, S. P. Aksenova, N. A. Rubtsova, V. E. Sinitsyn, T. P. Berezovskaia, S. V. Ivashina, V. G. Bychenko, A. V. Mishchenko, M. M. Khodzhibekova, et al.

    The article offers the latest view on possibilities of diagnostic algorithm to identify vaginal cancer (VC), rare tumor of the woman’s reproductive system. The algorithm is described as a consensus of leading expert in imaging diagnostics, as well as oncogynecologysts, investigating diagnostic challenges and vaginal cancer therapies. The article sets forth the principal trends in using imaging methods, their role and possibilities for staging VC, planning and assessing the efficacy of applied therapy, on-going surveillance over patients, who have undergone specialized anti-cancer treatment

  • Open Access

    Тerminology of rectal cancer: consensus agreement of the expert working group

    by Tatiana P. Berezovskaya, Natalia A. Rubtsova, Valentin E. Sinitsyn, Irina V. Zarodnyuk, Nicolai V. Nudnov, Andrei V. Mishchenko, Yuliya L. Trubacheva, Tatiana A. Bergen, Pavel Yu. Grishko, Svetlana S. Balyasnikova, et al.

    Unified terminology is a necessary condition for successful interdisciplinary communication within the field of oncology. The variety of anatomical, pathomorphological, and clinical terms used in rectal cancer is often accompanied by their ambiguous interpretation both in domestic and foreign scientific literature. This not only complicates the interaction between specialists, but also complicates the comparison of the results of rectal cancer treatment obtained in different medical institutions. Based on the analysis of recent domestic and international scientific and methodological literature on rectal cancer, the key terms used in the diagnosis and treatment planning of rectal cancer were selected, followed by a two-time online discussion of their interpretations by experts from the Russian Society of Radiologists and Therapeutic Radiation Oncologists, the Association of Oncologists of Russia, and the Russian Association of Therapeutic Radiation Oncologists until reaching consensus (80%) of experts on all items. Terms that fail to attain consensus were excluded in the final list. A list of anatomical, pathomorphological, and clinical terms used in the diagnosis, staging, and treatment planning of rectal cancer has been compiled and, based on expert consensus, their interpretation has been determined. A lexicon recommended in the description and formulation of the conclusion of diagnostic studies in patients with rectal cancer is proposed.